US EditionPublished • loading... • Updated
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
Regeneron will cut Praluent to $225 through TrumpRx and offer a newly approved hearing-loss gene therapy free in the United States.
- On Thursday, President Donald Trump announced that Regeneron Pharmaceuticals became the 17th major pharmaceutical company to join his 'most favored nation' pricing initiative, agreeing to reduce Medicaid prices and align future medications with global rates.
- Trump's push to lower U.S. drug costs began in May 2025 with announcement of the most favored nation policy, followed by letters sent last July to executives at 17 major pharmaceutical companies urging price cuts and MFN implementation.
- Regeneron will cut its cholesterol drug Praluent from $537 to $225 for TrumpRx buyers and pledged $27 billion by 2029 for U.S. research, development, and manufacturing, contributing to $448 billion in total pharmaceutical investments announced under Trump.
- Separately, the Food and Drug Administration approved Regeneron's gene therapy Otarmeni on Thursday for rare genetic hearing loss affecting about 50 children yearly; CEO Leonard Schleifer said the company will provide it free in the U.S. 'to show who we are.'
- Lawmakers pressed Health Secretary Robert F. Kennedy Jr. this week to release confidential contract terms, while experts caution that discounts apply mainly to Medicaid and TrumpRx, not affecting most Americans with private insurance or Medicare.
Insights by Ground AI
Podcasts & Opinions
26 Articles
26 Articles
Donald Trump managed to get 17 pharmaceutical companies to agree to lower the price of their medicines, the most recent of which was Regeneron Pharmaceuticals.
Coverage Details
Total News Sources26
Leaning Left3Leaning Right3Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 22%
C 57%
R 21%
Factuality
To view factuality data please Upgrade to Premium
